Rentschler Biopharma Appoints Former Bachem CCO Torsten Wöhr as CEO to Lead Next Growth Phase
核心洞察
Rentschler Biopharma SE has appointed Dr. Torsten Wöhr as Chief Executive Officer, effective August 1, 2026, succeeding interim CEO Prof. Dr. Uwe Buecheler.
Dr. Wöhr brings over 25 years of international CDMO and biotechnology experience, most recently serving as Chief Commercial Officer at Bachem Group (搜索).
The appointment marks the next phase of the company's corporate strategy focused on long-term growth and sustainable value creation.
Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today the appointment of Dr. Torsten Wöhr as Chief Executive Officer, effective August 1, 2026. The announcement was made from the company's dual headquarters in Laupheim, Germany, and Milford, MA, USA.
Dr. Wöhr brings more than 25 years of experience across the international CDMO and biotechnology industry, combining strong commercial leadership with deep operational understanding. Most recently, he served as Chief Commercial Officer of Bachem Group (搜索), where he led global commercial activities that drove major strategic investments, with a focus on sustainable growth. Prior to joining Bachem in mid-2017, he spent 20 years in various international leadership roles at companies including Johnson & Johnson, Genzyme, and Corden Pharma. His international experience includes more than a decade living in the United States. Dr. Wöhr holds a doctorate in bioorganic chemistry from the Swiss Federal Institute of Technology (EPFL) in Lausanne.
Leadership Transition and Strategic Vision
The appointment advances the next phase of the company's corporate strategy, aimed at further strengthening long-term growth and sustainable value creation. Following a period of interim leadership, Prof. Dr. Uwe Buecheler will step down as interim CEO and return to his role as Vice Chairman of the Supervisory Board, also effective August 1, 2026.
Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma, expressed confidence in the appointment: "I am delighted to welcome Mr. Wöhr to Rentschler Biopharma. He brings extensive transatlantic experience and a proven track record in the CDMO industry of successfully implementing commercial strategies for business growth and fostering impactful client engagement."
Rentschler further emphasized the strategic importance of the hire, noting: "At a time when our clients are navigating increasing complexity in biologics development and manufacturing, his expertise in aligning commercial priorities with operational capabilities and strengthening partnerships will be critical. I am confident that, under his leadership, we will continue creating value sustainably for our clients and their patients."
Incoming CEO's Perspective
Dr. Wöhr, incoming CEO of Rentschler Biopharma, commented on his new role: "Rentschler Biopharma is recognized for its trusted partnerships, scientific expertise and unwavering commitment to delivery for clients. I am excited to lead the company and look forward to working alongside the talented and dedicated teams across the organization."
He added: "We will build on this solid foundation to further enhance our capabilities and create lasting impact for our partners, our clients and patients worldwide. In doing so, we remain firmly guided by the vision of advancing medicine to save lives, together."
Acknowledgment of Interim Leadership
Prof. Dr. Nikolaus F. Rentschler also extended gratitude to the outgoing interim CEO: "I also sincerely thank Mr. Buecheler for his outstanding leadership during the transition period. His experience, guidance and dedication have ensured continuity, maintained strong momentum and positioned Rentschler Biopharma for its next phase of development. I am very pleased that he will continue to support the company in his role on the Supervisory Board."
About Rentschler Biopharma
Rentschler Biopharma SE is a leading CDMO focused exclusively on customer projects. The company offers process development and production of biopharmaceuticals, including novel therapies, as well as related consulting services, project planning, and regulatory support. The independent family-owned company employs approximately 1,400 people at its headquarters in Laupheim, Germany, and its site in Milford, MA, USA. In 2024, the company joined the United Nations Global Compact, underscoring its commitment to sustainability.